BCG-based vaccine compositions and methods of use thereof

The present disclosure relates to a therapeutic agent based on BCG using a BCG strain that overexpresses the STING agonist c-di-AMP. The BCG strain, referred to as BCG-disA-OE, enhances improved training immunity of macrophages and promotes early antiviral type I interferon responses in a subject, p...

Full description

Saved in:
Bibliographic Details
Main Authors COHEN KAYLA, YEGANASUBRAMANIAN, SRINIVASAN, WURM PETER, TRINITI J. BIVALACQUA, WANG RULIN, SINGH ALOK, BEESE WILLIAM
Format Patent
LanguageChinese
English
Published 01.08.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to a therapeutic agent based on BCG using a BCG strain that overexpresses the STING agonist c-di-AMP. The BCG strain, referred to as BCG-disA-OE, enhances improved training immunity of macrophages and promotes early antiviral type I interferon responses in a subject, providing protection against viral infections, such as primary respiratory infection and SARS-CoV-2 infection. 本公开内容涉及一种基于BCG的使用过表达STING激动剂c-di-AMP的BCG菌株的治疗剂。该BCG菌株，称为BCG-disA-OE，增强巨噬细胞的提高的训练免疫，并促进受试者中早期抗病毒I型干扰素应答，提供针对病毒感染诸如原发性呼吸系统感染和SARS-CoV-2感染的保护。
Bibliography:Application Number: CN202180081041